Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
about
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.NaPLK-1 Targeted Inhibitors and Their Potential against TumorigenesisA phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerChanging pathology with changing drugs: tumors of the gastrointestinal tract.Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
P2860
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Evaluation of the novel mitoti ...... f an ex vivo predictive assay.
@ast
Evaluation of the novel mitoti ...... f an ex vivo predictive assay.
@en
type
label
Evaluation of the novel mitoti ...... f an ex vivo predictive assay.
@ast
Evaluation of the novel mitoti ...... f an ex vivo predictive assay.
@en
prefLabel
Evaluation of the novel mitoti ...... f an ex vivo predictive assay.
@ast
Evaluation of the novel mitoti ...... f an ex vivo predictive assay.
@en
P2093
P2860
P356
P1433
P1476
Evaluation of the novel mitoti ...... of an ex vivo predictive assay
@en
P2093
J Wheelhouse
M V Ramana Reddy
P2860
P2888
P304
P356
10.1038/ONC.2008.424
P407
P577
2008-11-24T00:00:00Z